Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.

NCT00202644 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00202644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00202644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.
Lead sponsor
Shire
Phase
Phase 4
Overall status
Completed
Start date
January 13, 2006
Completion date
December 15, 2015
Enrollment
150 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

thrombocythemia, hemorrhagic